Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | FOS | P01100 | 1/20 | 0.62 |
| ▸ | JUN | P05412 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320363 | 1.00 | MAOB (0.62) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL5446308 | 0.91 | MAOB (0.62) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL9380767 | 0.87 | ALOX5 (0.80) | MAOBFOSJUNBCHENPC1 | |
| SCHEMBL9380757 | 0.87 | ALOX5 (0.80) | MAOBFOSJUNBCHENPC1 | |
| SCHEMBL15128596 | 0.86 | MAOB (0.54) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL3580362 | 0.83 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL29822711 | 0.83 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL3580365 | 0.83 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL9387783 | 0.83 | ALOX5 (0.66) | MAOBBCHEALOX5PTGS1PTGS2 | |
| SCHEMBL9387791 | 0.83 | ALOX5 (0.66) | MAOBBCHEALOX5PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024048438-A1 | DIASTEREOMER PREPARATION METHOD, AND SOLID-PHASE PHOTOSENSITIZER | 学校法人東京理科大学 | 2024-03-07 | — | — | WO | disclosed |
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10059667-B2 | Antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3102198-A1 | ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| EP-0747346-B1 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL MYERS SQUIBB CO (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5889031-A | CONTROLLING CIRCADIAN RHYTHMS | BRISTOL-MYERS SQUIBB COMPNAY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5753709-A | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0747346-A2 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | GPR119, GLP1R, GIPR | MAOB 4173/4885FOS 1796/4885JUN 2331/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | MAOB 3976/4885FOS 2547/4885JUN 3474/4885 |
| US-10059667-B2 | Antidiabetic compounds | GPR119, GLP1R, GIPR | MAOB 4173/4885FOS 1796/4885JUN 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.